Skip to main content

Advertisement

SpringerLink
Log in

A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

The pro-inflammatory interleukin (IL)-17A serum has been characterized in several systemic autoimmune diseases, but not in antisynthetase syndrome (ASS). Therefore, the present study aims firstly to assess the serum level of the IL-17A in patients with ASS, comparing with healthy individuals, and secondly to analyze prospectively this IL in patients with refractory ASS undergoing rituximab treatment.

Materials and methods

A cross-sectional, single-center study that included 64 patients with ASS who were age-, gender-, and ethnicity-matched to 64 healthy individuals. Disease status was measured by the International Myositis Assessment and Clinical Studies Group (IMACS) set scores. Secondarily, the patients with refractory disease treated with rituximab were prospectively followed for 12 months. The IL-17A was assessed by the ELISA method.

Results

The mean age of the patients was 44.8 ± 11.8 years, with a predominance of female gender and Caucasian. The median serum IL-17A level was higher in ASS patients compared with healthy individuals: 9.7 (9.1–10.4) vs. 7.7 (5.7–9.0) pg/mL, respectively, and P < 0.001. However, the demographical, clinical, and laboratory data indicates that disease status did not correlate with serum levels of the IL-17A in ASS patients. Prospectively, 16 patients received rituximab, and there was a drop of IL-17A serum level over the first year of treatment in these patients: from 9.7 (9.1–10.6) to 9.0 (8.2–9.7) pg/mL (P = 0.01).

Conclusions

Our study demonstrated that patients with ASS have increased serum levels of the IL-17A compared with healthy controls. In addition, the patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A.

Key Points

• Patients with ASS have increased serum levels of the IL-17A.

• Patients with refractory ASS treated with rituximab showed a reduction of the serum levels of the IL-17A.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gallay L, Gayed C, Hervier B (2018) Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol 30:664–673

    Article  CAS  Google Scholar 

  2. Araujo PAO, Silva MG, Borba EF, Shinjo SK (2018) High prevalence of metabolic syndrome in antisynthetase syndrome. Clin Exp Rheumatol 36:241–247

    PubMed  Google Scholar 

  3. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138:1464–1474

    Article  Google Scholar 

  4. Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, Cordier JF, Cottin V (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883–891

    Article  CAS  Google Scholar 

  5. Roşu A, Mǎrgǎritescu C, Stepan A, Muşetescu A, Ene M (2012) IL-17 patterns in synovium, serum and synovial fluid from treatment-naïve, early rheumatoid arthritis patients. Romanian J Morphol Embryol 53:73–80

    Google Scholar 

  6. Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149–162

    Article  CAS  Google Scholar 

  7. Monin L, Gaffen SL (2018) Interleukin 17 family cytokines: signaling and therapeutic implications. Cold Spring Harb Perspect Biol 10:A028522

    Article  Google Scholar 

  8. Mitsdoerffer M, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK et al (2010) Pro-inflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 107:14292–14297

    Article  CAS  Google Scholar 

  9. Reed AM, Crowson CS, Hein M, De Padilla CL, Olazagasti JM, Aggarwal R et al (2015) Biologic predictors of clinical improvement in rituximab-treated refractory myositis clinical rheumatology and osteoporosis. BMC Musculoskelet Disord 16:257

    Article  Google Scholar 

  10. Van De Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, DI Padova F, Koenders MI et al (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63:1507–1516

    Article  Google Scholar 

  11. Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P et al (2016) Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sjögren’s syndrome: a pilot study. Clin Exp Immunol 184:284–292

    Article  CAS  Google Scholar 

  12. Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 63:435–449

    Article  CAS  Google Scholar 

  13. Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW et al (2010) Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 30:221–225

    Article  CAS  Google Scholar 

  14. Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H (2018) Expression of interleukin-17 in primary Sjögren’s syndrome and the correlation with disease severity: a systematic review and meta-analysis. Scand J Immunol 87:e12649

    Article  Google Scholar 

  15. Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK (2018) Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 37:656–662

    PubMed  Google Scholar 

  16. Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE, Iannone F (2015) Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol 44:224–228

    Article  CAS  Google Scholar 

  17. Tournadre A, Miossec P (2012) Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 14:252–256

    Article  CAS  Google Scholar 

  18. Shen H, Xia L, Lu J, Xiao W (2011) Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 40:217–220

    Article  CAS  Google Scholar 

  19. Moran EM, Mastaglia FL (2014) The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord 24:943–952

    Article  Google Scholar 

  20. Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P (2003) Interleukin-17 increases the effects of IL-1 h on muscle cells : arguments for the role of T cells in the pathogenesis of myositis. J Neuro-Oncol 137:125–133

    CAS  Google Scholar 

  21. Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation (2017) 2016 American College of Rheumatology/European League against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis. Ann Rheum Dis 76:782–791

    Article  Google Scholar 

  22. Rider LLG, Koziol D, Giannini EEH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465–472

    Article  Google Scholar 

  23. Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:1–6

    Article  Google Scholar 

  24. Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1462–1473

    Article  Google Scholar 

  25. Cruellas MG, Dos Santos VV, Levy-Neto M, Souza FHC, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68:909–914

    Article  Google Scholar 

  26. Souza FHC, Araújo DB, Vilela VS, Bezerra MC, Simões RS, Bernardo WM et al (2019) Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol 59:6

    Article  Google Scholar 

  27. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ (2011) Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 41:674–679

    Article  CAS  Google Scholar 

  28. Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051–1057

    Article  CAS  Google Scholar 

  29. Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C et al (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 56:999–1007

    Article  CAS  Google Scholar 

  30. Souza FHC, Cruellas MGP, Levy-Neto M, Shinjo SK (2013) Síndrome antissintetase: Anti-PL-7, anti-PL-12 and anti-EJ. Rev Bras Reumatol 53:352–357

    Article  Google Scholar 

  31. Hervier B, Benveniste O (2013) Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 15:349

    Article  Google Scholar 

  32. Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367–371

    Article  CAS  Google Scholar 

  33. Sem M, Molber Ø, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome - a retrospective case series. Rheumatology 48:968–971

    Article  CAS  Google Scholar 

  34. Souza FHC, Miossi R, De Moraes JCB, Bonfá E, Shinjo SK (2018) Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 58:31

    Article  Google Scholar 

  35. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83

    Article  Google Scholar 

Download references

Funding

This study is funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (#2014/09079-1), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) (#303379/2018-9), and Faculdade de Medicina da USP–SP to SKS.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil

    Gustavo Luiz Behrens Pinto, Renata Casseb de Souza Carboni, Fernando Henrique Carlos de Souza & Samuel Katsuyuki Shinjo

Authors
  1. Gustavo Luiz Behrens Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renata Casseb de Souza Carboni
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fernando Henrique Carlos de Souza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samuel Katsuyuki Shinjo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Samuel Katsuyuki Shinjo.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Behrens Pinto, G.L., Carboni, R.C.d., de Souza, F.H.C. et al. A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome. Clin Rheumatol 39, 2763–2771 (2020). https://doi.org/10.1007/s10067-020-05013-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05013-7

Keywords

Search

Navigation